DrugPatentWatch Database Preview
Patent: 9,114,179
» See Plans and Pricing
Summary for Patent: 9,114,179
| Title: | Immunoconjugate formulations |
| Abstract: | The present invention provides an immunoconjugate formulation that is substantially free of particles, the immunoconjugate formulation comprising: an immunoconjugate and one or more excipients selected from the group consisting of: sucrose, polysorbate 20, polysorbate 80, cyclodextrin, dextrose, glycerol, polyethylene glycol, mannitol, sodium chloride, and an amino acid, wherein the formulation is a buffered aqueous solution having a pH of 4.5 to 7.6. The present invention also provides an immunoconjugate formulation that is substantially free of aggregates, the immunoconjugate formulation comprising: an immunoconjugate and one or more excipients selected from the group consisting of histidine, sucrose, glycine and sodium chloride, wherein the formulation is a buffered aqueous solution having a pH of 4.5 to 7.6. The present invention further provides an immunoconjugate formulation that is substantially free of both particles and aggregates. |
| Inventor(s): | Zhang; Wei (Philadelphia, PA), Fleming; Michael S. (Londonderry, NH), Amphlett; Godfrey (Cambridge, MA), Chih; Hung-wei (Burlingame, CA), Bartlett; Elizabeth (Cambridge, MA) |
| Assignee: | ImmunoGen, Inc. (Waltham, MA) |
| Application Number: | 11/498,139 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,114,179
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | HERCEPTIN HYLECTA | trastuzumab; hyaluronidase-oysk | INJECTABLE;SUBCUTANEOUS | 761106 | 001 | 2019-02-28 | Start Trial | ImmunoGen, Inc. (Waltham, MA) | 2025-08-03 | RX | search | |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 002 | 2017-06-22 | Start Trial | ImmunoGen, Inc. (Waltham, MA) | 2025-08-03 | RX | Orphan | search |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | Start Trial | ImmunoGen, Inc. (Waltham, MA) | 2025-08-03 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 9,114,179
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 200800146 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2007019232 | Start Trial |
| United States of America | 2007031402 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
